- Home
- General Medicine
- Risankizumab for Crohn’s Disease: Phase 3 Evidence and Practical Implications

1w3 min read
Medical Article
Introduction Crohn’s disease (CD) is a chronic inflammatory bowel disease characterized by relapsing and remitting inflammation of the gastrointestinal tract. Despite the availability of several biologic agents, many patients fail to achieve or sustain remission, particularly those with prior biologic failure. The pathogenesis of Crohn’s disease ha

Risankizumab for Crohn’s Disease: Phase 3 Evidence and Practical Implications
4 Reached1 Comments
Similar Content

Single-incision Laparoscopy for Gastrostomy
407 Reached2 Comments1 Likes

Intestinal Obstruction and Ileocolic Fistula due to Gossypiboma
861 Reached30 Comments15 Likes

Woman with Complaint of Spontaneous Massive Rectal Prolapse
1864 Reached17 Comments9 Likes

Study evaluating Effectiveness of Bacillus clausii for Treatment of Rotavirus Infection
1303 Reached4 Comments6 Likes

Safe Ramadan Practices during COVID-19 - WHO Guidance
5327 Reached8 Comments3 Likes